MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Britain Courts Anthropic Amid US Defense Department Dispute 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
VALENCIA, Calif., Jan. 27, 2017 -- MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) will host a conference call to discuss Company developments at 5:00 PM (Eastern Time) on February 1, 2017.
Presenting from the Company will be its Chief Executive Officer, Matthew Pfeffer and Chief Commercial Officer, Michael Castagna.
To participate in the live call by telephone, please dial (888) 771-4371 or (847) 585-4405 and use the participant passcode: 44112877. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at http://www.mannkindcorp.com under News & Events.
A telephone replay of the call will be accessible for approximately 14 days following completion of the call by dialing (888) 843-7419 or (630) 652-3042 and use the participant passcode: 4411 2877#. A replay will also be available on MannKind's website for 14 days.
About MannKind Corporation
MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) focuses on the discovery and development of therapeutic products for patients with diseases such as diabetes. MannKind maintains a website at http://www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.
Company Contact: Rose Alinaya SVP, Finance 661-775-5300 [email protected]
